Brought to you by 
Valeant gets rights to commercialize Orexigen's Mysimba in 19 European countries
04 Nov 2016
Executive Summary
Orexigen Therapeutics Inc. licensed Valeant Pharmaceuticals International Inc. rights to commercialize its obesity drug Mysimba (naltrexone HCl/bupropion HCl prolonged release) tablets in 19 countries in Central and Eastern Europe.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Valeant gets rights to commercialize Orexigen's Mysimba in 19 European countries
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice